244 0 Kommentare AgeX Therapeutics Publishes Theoretical Basis of Human Cell Age-Reversal in the Journal Regenerative Medicine

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging and regeneration, announced today that founder and CEO Michael D. West, Ph.D., and colleagues have authored a paper in the peer-reviewed scientific journal Regenerative Medicine on the theoretical foundation of the Company’s induced Tissue Regeneration (iTR^TM) technology. The paper presents the work of the company’s scientists in describing a unified theory of aging and regeneration that could pave the way for the development of new therapies for a variety of age-related degenerative diseases and conditions.

“The longevity sector is advancing at an accelerating pace, but for the most part, without a consensus on the fundamental root causes of aging,” commented Dr. West. “We believe that it is now possible to collate the diverse observations about aging into a unified model. In the paper titled, ‘Toward a Unified Theory of Aging and Regeneration’ we outline such a theory that underlies the technological underpinnings of the company’s induced tissue regeneration (iTR) program.”

The paper explores the mechanisms of aging and shares important insights into molecular biology of cell aging and immortalization, as well as the mechanisms of cell age reversal by somatic cell nuclear transfer and transcriptional reprogramming. Lastly, the paper explores the prospects of cell age reversal in vivo, that is in the patient, as opposed to in vitro (the laboratory dish).

“We are fortunate to have at AgeX some of the first scientists in the world to envision applying reprogramming technology to the problems of aging,” commented Greg Bailey, M.D., Chairman of the Board of Directors. “Our ultimate aim is to not only lead in the basic research in this new field, but to also lead in the translation of the science into safe and effective therapeutics for the aging population. To accomplish the latter goal, we have incorporated a new subsidiary of AgeX, Reverse Bioengineering, Inc. with the primary mission of advancing this emerging technology.”

Co-authors on the paper are Hal Sternberg, PhD, Ivan Labat, PhD, Jeffrey Janus, Karen B. Chapman, PhD, Nafees N. Malik, MD, Aubrey D.N.J. de Grey, PhD, and Dana Larocca, PhD.